10-Q: Doximity Q2 Revenue Jumps 23%, Net Income Up 40%

Doximity, Inc. reports strong second-quarter fiscal 2026 results with significant revenue and net income growth, driven by subscription expansion and a strategic AI acquisition.

Summary

• Revenue for the three months ended September 30, 2025, increased by 23% to $168.5 million, up from $136.8 million in the prior year period.
• Net income for the three months ended September 30, 2025, rose by 40% to $62.1 million, compared to $44.2 million in the same period last year.
• Adjusted EBITDA for the three months ended September 30, 2025, grew by 32% to $100.8 million, up from $76.1 million in the prior year period.
• The net revenue retention rate increased to 118% as of September 30, 2025, from 116% in the prior year.
• The number of customers with trailing 12-month subscription revenue greater than $500,000 increased to 121 as of September 30, 2025, from 104 in the prior year.
• Doximity completed the acquisition of Pathway Medical Inc., an AI-based medical knowledge platform, on July 29, 2025, for $36.3 million.
• The company repurchased $144.2 million of Class A common stock during the six months ended September 30, 2025, with $279.8 million remaining under the authorized $500 million program.
• General and administrative expenses increased significantly by 89% for the three months and 63% for the six months ended September 30, 2025, primarily due to higher legal expenses, stock-based compensation, and acquisition-related costs.
• The effective tax rate decreased to 14.9% for the three months and 15.8% for the six months ended September 30, 2025, partly due to stock-based compensation tax benefits and the impact of the Tax Act (H.R. 1) allowing accelerated R&D expense deductions.

Sentiment

Score: 8

Explanation: The company delivered robust revenue and net income growth, maintained high gross margins, and showed strong customer retention. The acquisition of Pathway Medical Inc. enhances its AI capabilities. However, the significant increase in legal expenses and ongoing litigation, including a new cyberattack lawsuit, introduce considerable uncertainty and potential financial liabilities.

Positives

• Strong revenue growth of 23% for the quarter ($168.5 million) and 19% for the six months ($314.4 million).
• Significant net income increase of 40% for the quarter ($62.1 million) and 35% for the six months ($115.4 million).
• Adjusted EBITDA grew by 32% for the quarter ($100.8 million) and 27% for the six months ($180.6 million).
• Gross margin remained consistently high at 90% for both the three and six months ended September 30, 2025 and 2024.
• Net revenue retention rate improved to 118%, indicating strong customer loyalty and expansion within existing accounts.
• The number of high-value customers (>$500,000 TTM subscription revenue) increased from 104 to 121, demonstrating growth in key customer segments.
• Strategic acquisition of Pathway Medical Inc., an AI-based medical knowledge platform, enhances the company's technology and engineering capabilities.
• Maintained strong liquidity with $878.4 million in cash, cash equivalents, and marketable securities as of September 30, 2025.
• Active share repurchase program, with $279.8 million remaining authorized, signaling confidence in valuation and returning capital to shareholders.
• The recently enacted Tax Act (H.R. 1) allowed for accelerated deduction of domestic R&D expenses, positively impacting the company's tax position.

Negatives

• Cash and cash equivalents decreased by $40.4 million from $209.6 million at March 31, 2025, to $169.2 million at September 30, 2025.
• Deferred revenue (current) decreased from $114.3 million at March 31, 2025, to $100.0 million at September 30, 2025, due to timing of customer billings and program launches.
• Retained earnings decreased from $186.9 million at March 31, 2025, to $157.7 million at September 30, 2025, primarily due to significant share repurchases.
• General and administrative expenses increased substantially by 89% for the three months and 63% for the six months ended September 30, 2025, driven by higher legal expenses, stock-based compensation, and acquisition-related costs.
• Ongoing legal proceedings, including a securities class action and multiple shareholder derivative lawsuits, pose potential financial and reputational risks.
• A new lawsuit from OpenEvidence Inc. alleges unauthorized access and cyberattacks against their AI medical information platform, which could result in significant damages and injunctions.
• Deferred income tax assets decreased significantly from $60.0 million at March 31, 2025, to $15.1 million at September 30, 2025, partly due to the acceleration of R&D expense deductions under the Tax Act.

Risks

• The company is currently subject to significant litigation, including a securities class action and multiple shareholder derivative lawsuits, which could result in substantial defense costs, judgments, fines, or settlements.
• A new lawsuit from OpenEvidence Inc. alleges unauthorized access and cyberattacks, potentially leading to permanent injunctions, actual damages, and disgorgement of profits.
• Failure to successfully identify, negotiate, acquire, and integrate new or complementary businesses, technologies, tools, or solutions, such as Pathway Medical Inc., could materially and adversely affect the business.
• Acquisitions may not yield expected returns, potentially requiring impairment charges to goodwill and other intangible assets.
• Operating in a very competitive and rapidly changing environment poses risks from existing competitors and new market entrants.
• The company's ability to maintain, protect, and enhance its intellectual property rights is crucial, and associated costs or failures could be detrimental.
• Maintaining data privacy and data security is a continuous challenge, and breaches could harm the business and reputation.
• The ability to effectively manage growth, including identifying, retaining, and recruiting personnel, and maintaining company culture, is critical.
• Future regulatory, judicial, and legislative changes or developments could impact customers or the business.
• The dual-class common stock structure may present risks related to Class A common stock holders' voting power.

Future Outlook

The company anticipates an increase in research and development expenses as it expands its platform and product offerings. Sales and marketing expenses are also expected to rise and become the largest expense category on an absolute basis. General and administrative expenses are projected to increase due to compliance costs associated with being a publicly-traded company. Management believes current cash, cash equivalents, and marketable securities will cover working capital and capital expenditure needs for at least the next 12 months, but may seek additional financing for future acquisitions or investments. The number of shares for certain performance-based restricted stock units (PSUs) is expected to become fixed in the fourth quarter of fiscal 2026, at which point the related liability will be reclassified to equity.

Management Comments

• Our mission is to help every physician be more productive and provide better care for their patients.
• We are physicians-first, putting technology to work for doctors instead of the other way around.
• Our business model has delivered high revenue growth at scale with profitability.
• We intend to continue to invest additional resources in our cloud infrastructure and our customer support organizations to support the growth of our business.
• We expect our gross margin to remain relatively steady over the near term, although our quarterly gross margin is expected to fluctuate from period to period depending on the interplay of these and other factors.
• We generally intend to defend ourselves vigorously against legal actions; however, we cannot be certain of the ultimate outcomes of any claims currently pending or that may arise in the future.

Industry Context

Doximity maintains its position as the leading digital platform for U.S. medical professionals, serving over 80% of U.S. physicians. The company's strategic acquisition of Pathway Medical Inc., an AI-based medical knowledge platform, aligns with the broader healthcare industry trend of integrating artificial intelligence for administrative efficiency and clinical decision support. Continued investment in telehealth and workflow solutions reflects the ongoing demand for digital tools that enhance physician productivity and patient care, positioning Doximity to capitalize on the digital transformation within healthcare.

Comparison to Industry Standards

• Doximity's claim as the 'leading digital platform for U.S. medical professionals' with 'more than 80% of U.S. physicians' indicates a dominant market share, surpassing many competitors in user penetration.
• A net revenue retention rate of 118% is a strong performance metric, often exceeding the average for many SaaS companies, demonstrating high customer satisfaction and successful upselling/cross-selling.
• The consistent 90% gross margin is exceptionally high, indicating superior operational efficiency and cost management compared to typical software or digital platform companies.
• The acquisition of Pathway Medical Inc., an AI-based medical knowledge platform, positions Doximity to compete with other digital health innovators investing in AI, such as Google Health or Microsoft's healthcare initiatives, by enhancing its AI capabilities for administrative tasks and clinical decision support.

Corporate Governance

Legal Proceedings

• In re Doximity, Inc. Securities Litigation (No. 5:24-cv-02281, N.D. Cal.): Securities law claims on behalf of a putative class of investors (June 24, 2021 August 8, 2023) against the Company and CEO related to disclosure of user count and engagement rates. Currently in discovery phase.
• In re Doximity, Inc. Stockholder Derivative Litigation (No. 5:24-cv-02801, N.D. Cal.): Consolidated shareholder derivative lawsuits asserting claims for violations of securities law, breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and waste against certain directors and officers.
• Guttman v. Tangney, et al. (1:24-cv-01387, D. Del.) and Wong v. Tangney, et al. (No. 1:25-cv-750, D. Del.): Shareholder derivative lawsuits filed in the U.S. District Court for the District of Delaware.
• Stern v. Tangney, et al. (No. 2025-0661, Del. Ch.): Shareholder derivative lawsuit filed in the Court of Chancery of the State of Delaware.
• OpenEvidence Inc. v. Doximity, Inc. et al. (No. 1:25-cv-11802-RGS, D. Mass.): Lawsuit filed June 20, 2025, against the Company, CTO, and Director of AI Products. Amended October 29, 2025, adding Pathway Medical, Inc. and other individuals as defendants. Alleges unauthorized access and cyberattacks against OpenEvidence's AI medical information platform, claiming violations of the Computer Fraud and Abuse Act (CFAA), breach of contract, unjust enrichment, and trespass to chattels. Defendants filed counterclaims for false advertising, Massachusetts Consumer Protection Law violations, and common law defamation. Plaintiff seeks permanent injunction, return/destruction of information, actual damages, and defendants' profits.

Stakeholder Impact

• Shareholders: Positive impact from strong financial performance, share repurchase program, and strategic acquisition. Negative impact from ongoing legal proceedings which could lead to significant financial liabilities and potentially affect share price.
• Employees: Positive impact from new equity awards and potential for growth through acquisitions. Pathway Medical employees joining Doximity.
• Customers: Benefit from enhanced platform capabilities through the Pathway Medical acquisition and continued investment in product offerings. Strong net revenue retention rate indicates high customer satisfaction.
• Competitors: Doximity's strong growth and strategic acquisition could intensify competition in the digital health and AI medical platform space.
• Regulatory Authorities: The company is subject to ongoing compliance costs and potential scrutiny related to legal proceedings.

Next Steps

• Continue to vigorously defend against ongoing securities litigation, shareholder derivative lawsuits, and the OpenEvidence Inc. lawsuit.
• Evaluate the impact of recently issued accounting pronouncements (ASU 2023-09, ASU 2024-03, ASU 2025-05, ASU 2025-06) on consolidated financial statements and disclosures.
• Establish performance targets for an additional $8 million of PSUs over fiscal years 2027 and 2028.
• Continue the Class A common stock repurchase program, with $279.8 million remaining authorized.
• Manage the integration of Pathway Medical Inc. to realize expected benefits.
• The number of shares for certain PSUs will become fixed in the fourth quarter of fiscal 2026, leading to reclassification of the liability to equity.
• Individual awards from the $30 million equity award pool will vest on a quarterly basis through the fourth quarter of fiscal 2027.

Key Dates

Recommendation

Doximity demonstrates robust financial health with impressive revenue and profit growth, coupled with strong customer retention and a strategic acquisition in AI. This indicates a solid core business and growth trajectory. However, the increasing legal challenges, including a securities class action and a new lawsuit alleging cyberattacks, introduce substantial unquantifiable risks and potential liabilities. The significant increase in general and administrative expenses, partly due to legal fees, highlights the immediate financial impact of these issues. While the operational performance is strong, the legal overhang warrants caution, suggesting a 'Hold' position until there is greater clarity on the potential outcomes and financial implications of the litigation.

Keywords

Doximity, Healthcare technology, Medical professionals network, AI medical platform, SEC filing, 10-Q, Financial results, Q2 2025, Subscription revenue, Adjusted EBITDA, Pathway Medical acquisition, Legal proceedings, Share repurchase, Digital health, Pharmaceutical marketing, Health systems, Telehealth, AI writing assistant